Search results
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Zacks via Yahoo Finance· 2 days agoThe PTCT stock gained on the positive update as investors cheered the regulatory development. PTC...
Robeco Institutional Asset Management B.V. Sells 180,219 Shares of Biogen Inc. (NASDAQ:BIIB)
ETF DAILY NEWS· 7 hours agoRobeco Institutional Asset Management B.V. trimmed its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 52.7% in the 4th quarter, according to its most recent 13F filing ...
IGM Biosciences stock surges as Biogen's deal for HI-Bio is seen as a positive
Investing.com· 3 days agoIGM Biosciences stock surges as Biogen's deal for HI-Bio is seen as a positive
...Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (...
Benzinga· 14 hours agoRobbins LLP informs investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Biogen Inc. BIIB securities between ...
Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers -...
WTNH-TV New Haven· 3 days agoPomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the"Company") (NASDAQ: BIIB) and certain officers. The class action, filed ...
BIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with...
Morningstar· 2 days agoThe law firm ofRobbins Geller Rudman & Dowd LLP announces that the Biogen class action lawsuit seeks to represent purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB) securities ...
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Zacks· 3 days agoFree Report) announced that the FDA has removed the partial clinical hold on its nomlabofusp (CTI-1601) clinical program following a review of the phase II dose exploration study data. Shares ...
Biogen to buy San Francisco startup developing a drug for kidney disease for $1.2B - Boston Business...
The Business Journals· 3 days agoBiogen Inc. is shelling out $1.15 billion upfront to buy a South San Francisco immunology company....
